Valuation dashboard for Dyadic International, Inc. (DYAI) with P/E N/A, P/B -6.38, EV/EBITDA -3.14 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies.
Analysis Summary
Dyadic International, Inc. reported revenue of $1.2M in the most recent fiscal year, growing at a 5-year CAGR of -5.1%.
Trailing-twelve-month margins: gross margin 30.4%, operating margin -213.6%, net margin -219.5%.
At the current price of $0.40, DYAI has negative trailing earnings (P/E not meaningful) and an ROE of -29.18%. Market capitalisation stands at $15M.
Balance sheet quality for DYAI: current ratio of 2.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -6.38 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DYAI | Dyadic International, Inc. | $15M | -29.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.40 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -2918.10% |
| Return on Invested Capital | -278.95% |
| Return on Assets | -116.60% |
| Gross Margin | 30.44% |
| Operating Margin | -213.59% |
| Net Margin | -219.50% |
Related companies: ANVS · ATHE · BCAB · CELU · ELUT · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of DYAI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks